Investor Relations Roundtable
The T2B Investor Relations Roundtable empowers biopharma communicators to navigate the complex investor landscape and integrate IR seamlessly into broader corporate affairs strategies. Supporting professionals across all levels, the roundtable fosters collaboration and equips members with tools to enhance trust, credibility, and effective communication with the IR community and beyond.
Roundtable objectives
- Facilitate knowledge-sharing to effectively engage investors, analysts, and other key stakeholders amid global market dynamics.
- Develop frameworks for integrating IR into corporate communications, ensuring consistent and cohesive messaging.
- Align evolving corporate affairs priorities with IR considerations spanning crisis communications, critical data readouts, ESG reporting, and expanding investor bases.
- Strengthen T2B’s programming with IR-focused resources and connections that address real-world challenges and opportunities.
Why join
- Leverage your background and experience in biopharma investor relations into a forum for relevant conversations and sharing insights with your colleagues in the industry.
- Work collaboratively in determining how best to address investor relations amid real-world challenges and evolving global market dynamics.
- Play a role in developing frameworks and best practices for the biopharma industry on how to integrate investor relations into broader communications strategy.
- Build meaningful connections and elevate your reputation as an investor relations thought leader within T2B’s community of communicators.
Eligibility requirements
Applicants must have:
- A basic understanding of and experience in biopharma investor relations with current or prior experience on the agency, corporate (in-house), or consulting side.
- The ability to volunteer 3-5 hours/month to co-create quarterly IR events and monthly resources for the broader T2B community.
- The commitment to actively participate in quarterly roundtable meetings as well as contribute ideas and feedback.
- An active T2B Pro membership.
About the chair
Ami Bavishi, Managing Director, Gilmartin Group LLC
Ami is an experienced investor relations professional with over 15 years of experience in biotech investor relations, through both agency and corporate (in-house) roles. She is currently a Managing Director at Gilmartin Group LLC. Prior to joining Gilmartin, Ami was the Executive Director, Head of Investor Relations and Corporate Communications at Rallybio, where she was responsible for overseeing the Company’s investor relations (IR) and communications efforts, including shaping the IR and communications strategies. Prior to joining Rallybio, Ami was the Director of Investor Relations at Aerie Pharmaceuticals Inc., where she oversaw all IR activities. Ami spent the majority of her career in roles of increasing responsibility at Burns McClellan, a New York-based life science IR and public relations firm, where she developed and managed various public company IR programs for various biotechnology and specialty pharmaceutical clients, as well as oversaw several of the firm’s investor days. Outside of IR, Ami also spent a year in business development with UK Trade and Investment, where she was responsible for assisting US-based biotechnology and medical device companies understand the business opportunities that exist in the United Kingdom.
Ami holds a master’s in public health in epidemiology from The George Washington
University and a bachelor’s in biology from Duquesne University.
Apply
Applications are closed and will reopen in April 2026. Each member term is for one calendar year.
“I am excited to lead the Investor Relations Roundtable for T2B as the IR role continues to evolve in our industry amidst the ever-changing global markets. I hope that the roundtable will be able to share our collective knowledge and experiences to develop relevant and important IR resources and guides, such as aligning IR with corporate communications, as well as brainstorm how to more effectively engage with the broader Wall Street community.”
